Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Feb;9(1):13-8.
doi: 10.1007/s10194-008-0009-y. Epub 2008 Jan 24.

Pharmacogenomics and migraine: possible implications

Peer Tfelt-Hansen  1 , Kim Brøsen
Affiliations
Review

Pharmacogenomics and migraine: possible implications

Peer Tfelt-Hansen et al. J Headache Pain. 2008 Feb.

Abstract

Pharmacogenomics is the science about how inherited factors influence the effects of drugs. Drug response is always a result of mutually interacting genes with important modifications from environmental and constitutional factors. Based on the genetic variability of pharmacokinetic and in some cases pharmacodynamic variability we mention possible implications for the acute and preventive treatment of migraine. Pharmacogenomics will most likely in the future be one part of our therapeutic armamentarium and will provide a stronger scientific basis for optimizing drug therapy on the basis of each patient's genetic constitution.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Pain-free response after 2 h for placebo (n = 63), and subcutaneous naratriptan (Na) (0.5 mg (n = 69), 1 mg (n = 55), 2.5 mg (n = 42), 5 mg (n = 34), 10 mg (n = 34), and sumatriptam 6 mg (n = 47) [12]
See this image and copyright information in PMC

References

    1. http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml
    1. Giacomini KM, Brett CM, Altman RB, Benowitz WL, Dolan ME, Flockhart DA, for the Pharmacogenetic Research Network et al. The pharmacogenetics research network: from SNP to clinical drug response. Clin Pharmacol Ther. 2007;81:328–345. doi: 10.1038/sj.clpt.6100087. - DOI - PMC - PubMed
    1. Lipton RB, Bigal ME, Stewart WF. Clinical trials of acute treatment for migraine including multiple attacks studies of pain, disability, and health-related quality of life. Neurology. 2005;65(Suppl 4):S50–S58. - PubMed
    1. Schürks M, Kurth T, Stude P, Rimmbach C, Jesus J, Jonjic M, Diener H-C, Rosskopf D. G protein β3 polymorphism and triptan response in cluster headache. Clin Pharmacol Ther. 2007;82:396–401. doi: 10.1038/sj.clpt.6100159. - DOI - PubMed
    1. Ophoff RA, Maagdenberg AM, Roon KI, Ferrari MD, Frants RR. The impact of pharmacogenetics for migraine. Eur J Pharmacol. 2001;413:1–10. doi: 10.1016/S0014-2999(00)00949-3. - DOI - PubMed

Substances